A global biotechnology company wanted to forecastmarket potential for their oral TKI inhibitor of the HER2 protein, which had been approved for oncology indication for all major markets.

Viscadia was asked to design and build an epidemiology-based patient flow model to construct a market landscape and assess product potential across 22 different markets around the world, while also incorporating regional nuances specific to several key markets.